Adjuvant therapy for women with high-risk endometrial carcinoma
Mené sur 660 patientes atteintes d'un cancer de l'endomètre à haut risque de récidive (durée médiane de suivi : 60,2 mois), cet essai international de phase III évalue, du point de vue de la survie sans échec, de la survie globale et des effets secondaires, l'intérêt d'une chimiothérapie par cisplatine-carboplatine-paclitaxel durant et après une radiothérapie
Identification of optimal therapy for patients with high-risk endometrial carcinoma has been frustrated by near-dichotomous paradigms of surgical treatment in the international community and a scarcity of level 1 data to inform adjuvant treatment. For example, at a meeting of the European Society for Medical Oncology–European Society of Gynaecological Oncology–European Society for Radiotherapy and Oncology Endometrial Consensus Conference Working Group, 14 recommendations were supported by level 1 or 2 evidence out of 50 nonsurgical treatment topics.1 However, the emergence of successful international cooperatives will accelerate the pace of innovation and learning worldwide, which will be welcome news indeed for both treating clinicians and patients who suffer from endometrial cancer. In The Lancet Oncology, the third successive randomised trial of endometrial cancer treatment is presented by Stephanie M de Boer and colleagues2 and the PORTEC group on behalf of seven participating countries.
The Lancet Oncology , commentaire en libre accès, 2017